Been looking at INSP lately and honestly the setup here is pretty compelling if you're thinking medium-term holds. The stock's down about 25% over six months while the broader industry fell 35%, so there's already some relative strength baked in.

Here's what caught my attention. Inspire Medical is basically the only player doing minimally invasive implants for sleep apnea, and they've already treated 125k+ patients globally. That's a serious moat. The company's been beating earnings consistently - we're talking 185% average surprise across the last four quarters. That's not noise.

The regulatory environment is opening up too. FDA expanded eligibility criteria back in 2023, raising the BMI threshold and apnea index limits. More recently they cleared the Inspire V neurostimulator which simplifies the whole implant procedure. Management noted over 90% of their centers have already adopted it, which is solid adoption velocity.

What's interesting from an R&D perspective is their PREDICTOR study looking at how factors like average neck circumference and BMI can predict which patients actually need the screening process. If they can streamline patient selection using average neck circumference measurements and other metrics, that's huge for scaling. Fewer unnecessary procedures means better margins and faster adoption.

The balance sheet is clean too - $308 million in cash, zero debt. No solvency concerns hanging over this.

Now the risks are real. This is essentially a one-product company. If Inspire therapy hits adoption ceiling or faces reimbursement pushback, there's nowhere else to hide. Some patients won't do implants, some won't tolerate side effects. That's structural risk you can't ignore.

But the earnings revisions are moving positive - consensus for 2026 EPS just moved up 21 cents to $1.93. That's the market pricing in the new product cycle and expanded market opportunity.

For a hold right now, I get it. You're not betting the farm but you're positioned for the next leg if the V rollout continues executing. The average neck circumference research and patient stratification improvements could be the quiet catalyst that drives efficiency gains over the next few quarters.